Core Viewpoint - The article discusses the tightening regulations on medical advertising in response to the increasing prevalence of misleading advertisements disguised as health information, particularly in the context of the internet's rapid development [1][3]. Summary by Sections Medical Advertising Regulation Challenges - Medical advertising has become more complex with the rise of the internet, leading to a blurring of lines between health education and advertising [1]. - In the first half of the year, regulatory authorities handled 1,666 cases of illegal medical advertising, imposing fines totaling 12.78 million yuan [1]. Introduction of the Recognition Guidelines - The State Administration for Market Regulation, in collaboration with the National Health Commission and the National Administration of Traditional Chinese Medicine, has developed the "Medical Advertising Recognition Guidelines" to clarify what constitutes medical advertising [3][4]. - The guidelines emphasize the importance of legitimate advertising entities and aim to address issues related to unqualified "black hospitals" and "black doctors" misleading the public [3]. Key Changes in the Guidelines - The guidelines prohibit any entity or individual, except legally established medical institutions, from publishing medical advertisements [4]. - The previous ambiguous definitions regarding promotional activities and health education have been removed, tightening the criteria for what constitutes advertising [4]. - The guidelines specify that linking health education content to medical services or products constitutes disguised advertising [4]. Focus on Internet Platforms - The rise of internet platforms has increased the volume of medical advertising, making it difficult for consumers to distinguish between advertising and educational content [6]. - Recent policies in Beijing aim to enhance compliance and promote legal awareness regarding medical advertising on digital platforms [6]. Collaborative Regulatory Efforts - The guidelines call for a coordinated approach among various regulatory bodies to effectively manage medical advertising [8]. - Local market supervision bureaus are collaborating with health and law enforcement departments to create a comprehensive regulatory network [8]. - A tiered regulatory approach is being implemented to avoid one-size-fits-all enforcement, allowing for leniency in minor violations [8].

风险提示：股市有风险，投资需谨慎。 公司境外控股子公司阿卡邦2025年半年度报告显示，其净利润为2877万元，同比下降13.29%。营业收 入4.52亿元，同比下降3.27%。利润下滑主要由于自营店铺增加导致商场费用上升，以及汇率变化影 响。 截至2025年8月14日15时，朗姿股份股价报17.21元，较前一交易日下跌0.54元，跌幅3.04%。当日开盘 价为17.75元，最高触及17.78元，最低下探至17.20元，成交量为94110手，成交金额达1.65亿元。 8月14日主力资金净流出4059.90万元，占流通市值0.93%。近五个交易日累计净流出7755.09万元，占流 通市值1.77%。 朗姿股份主营业务涵盖服装设计、生产和销售，同时涉及医疗美容服务等业务领域。公司旗下拥有多个 自主品牌，并通过境外子公司阿卡邦开展业务。 来源:金融界 ...

Group 1 - Tongda Power achieved a net profit of 42.64 million yuan in the first half of 2025, a year-on-year increase of 32.49% [1] - The company reported an operating income of 971 million yuan, up 22.07% year-on-year [1] - Basic earnings per share were 0.26 yuan [1] Group 2 - Hengshen New Materials reported a net loss of 36.70 million yuan in the first half of 2025, compared to a loss of 10.37 million yuan in the same period last year [2][3] - The company's operating income decreased by 24.84% to 1.22 billion yuan [2] Group 3 - Yiming Pharmaceutical's net profit was 37.56 million yuan, down 5.27% year-on-year [4] - The company experienced an 11.52% decline in operating income, totaling 311 million yuan [4] - Basic earnings per share were 0.20 yuan [4] Group 4 - Wangsu Technology achieved a net profit of 37.30 million yuan, a year-on-year increase of 25.33% [5] - The company's operating income was 2.35 billion yuan, up 2.19% year-on-year [5] - Basic earnings per share were 0.1524 yuan [5] Group 5 - Alloy Investment reported a net profit of 4.58 million yuan, a year-on-year increase of 44.12% [6] - The company achieved an operating income of 164 million yuan, up 73.46% year-on-year [6] - Basic earnings per share were 0.0119 yuan [6] Group 6 - Yifan Pharmaceutical's net profit was 30.40 million yuan, a year-on-year increase of 19.91% [8] - The company's operating income was 2.635 billion yuan, up 0.11% year-on-year [8] - Basic earnings per share were 0.25 yuan [8] Group 7 - Guoyao Yizhi reported a net profit of 66.60 million yuan, a year-on-year decrease of 10.43% [9] - The company's operating income was 36.797 billion yuan, down 2.62% year-on-year [9] - Basic earnings per share were 1.20 yuan [9] Group 8 - Hanjia Design expects a net profit of 15 to 16.5 million yuan, a year-on-year increase of 303.20% to 343.52% [10] - The company anticipates a net profit excluding non-recurring gains and losses of 14.5 to 17.5 million yuan, a year-on-year increase of 867.05% to 1067.13% [10] Group 9 - Gansu Energy Chemical announced the resumption of production at its Jinhe Coal Mine after passing safety inspections [16] Group 10 - Chuanjin Nuo reported a net profit of 177 million yuan, a year-on-year increase of 166.51% [18] - The company's operating income was 1.744 billion yuan, up 27.91% year-on-year [18] - Basic earnings per share were 0.6457 yuan [18] Group 11 - Yachuang Electronics achieved a net profit of 40.82 million yuan, a year-on-year increase of 1.47% [19] - The company's operating income was 2.847 billion yuan, up 125.74% year-on-year [19] - Basic earnings per share were 0.29 yuan [19] Group 12 - Yiheda reported a net profit of 282 million yuan, a year-on-year increase of 26.49% [14] - The company's operating income was 1.461 billion yuan, up 18.70% year-on-year [14] - Basic earnings per share were 0.44 yuan [14] Group 13 - Hatao Technology reported a net profit of 38 million yuan, a year-on-year increase of 233.08% [33] - The company's operating income was 1.475 billion yuan, up 1.12% year-on-year [33] - Basic earnings per share were 0.18 yuan [33] Group 14 - Anlu Technology announced that shareholders plan to reduce their holdings by no more than 3.25% of the company's shares [35] Group 15 - Baolidi reported a net profit of 63.81 million yuan, a year-on-year increase of 15.19% [36] - The company's operating income was 676 million yuan, up 1.47% year-on-year [36] - Basic earnings per share were 0.36 yuan [36] Group 16 - Harta Technology reported a net profit of 33.50 million yuan, a year-on-year increase of 55.61% [38] - The company's operating income was 335 million yuan, up 22.54% year-on-year [38] - Basic earnings per share were 0.0698 yuan [38] Group 17 - Huaxia Biological's controlling shareholder received a loan commitment of up to 250 million yuan from China Merchants Bank [58]

从资金流向上来看，当日医疗美容板块主力资金净流出1.01亿元，游资资金净流入4340.59万元，散户资 金净流入5715.55万元。医疗美容板块个股资金流向见下表： 证券之星消息，8月14日医疗美容板块较上一交易日下跌1.86%，华熙生物领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.15 | 0.00% | 10.44万 | 3292.65万 | | 832982 | 锦波生物 | 296.75 | -1.57% | 1.06万 | 3.15 Z | | 300896 | 爱美客 | 182.56 | -1.85% | 3.60万 | 6.66 Z | | 688363 | 华熙生物 | 52.50 | -2.05% | 4.12万 | 2.19亿 | | 代码 | | | 名称 | | | | | --- | --- | ...

Core Viewpoint - The joint release of the "Medical Advertising Recognition Guidelines" by the State Administration for Market Regulation, the National Health Commission, and the National Administration of Traditional Chinese Medicine aims to combat misleading medical advertisements and clarify the responsibilities of medical institutions in advertising [1][2]. Group 1: Regulatory Measures - The guidelines strictly limit the publication of medical advertisements to legally established medical institutions, prohibiting any individual or entity from publishing medical advertisements independently or through others [2]. - The guidelines address the issue of misleading advertisements disguised as medical information or health education, specifying which forms of information disclosure and health education do not constitute advertisements, while also listing specific scenarios where such disclosures are misused [2]. - The guidelines establish institutional arrangements for the transfer of leads and situation reporting between market regulation departments and health authorities to effectively address the chaos in medical advertising [2]. Group 2: Enforcement Actions - In the first half of 2025, market regulation departments across the country handled 1,666 cases of illegal medical advertising, with fines totaling 12.78 million yuan [1]. - The State Administration for Market Regulation has publicly exposed 30 typical cases of illegal advertisements in three batches, covering various sectors including medical beauty and medical devices, creating a strong deterrent effect [1]. - The guidelines are part of a broader effort to enhance collaboration between market regulation departments and health authorities, establishing a regular mechanism for joint assessment and enforcement [2].

风险提示：股市有风险，投资需谨慎。 来源：金融界 截至2025年8月13日收盘，皓宸医疗报3.52元，较前一交易日下跌1.12%。当日股价波动剧烈，最高触及 3.80元，最低下探3.35元，振幅达12.64%。全天成交194.78万手，成交金额6.90亿元。 8月13日盘中，皓宸医疗出现快速波动。早盘9点35分出现快速反弹，5分钟内涨幅超过2%；随后在10点 29分又出现快速回调，5分钟内跌幅超过2%。 资金流向方面，8月13日主力资金净流出204.57万元，占流通市值的0.07%。近五个交易日主力资金累计 净流入1.96亿元，占流通市值的6.63%。 皓宸医疗主营业务涵盖医疗服务和医疗美容领域。公司注册地位于吉林省，是一家专注于医疗健康产业 的企业。 ...

Financial Data and Key Metrics Changes - Total revenue declined by 18% year on year due to strategic restructuring and increased point redemption by customers [5][6][21] - The elevated effective tax rate was primarily due to non-deductibility of some executive compensation and temporary timing differences in aircraft sales recognition [6][7] Business Line Data and Key Metrics Changes - The average customer spending is trending lower than last year, but there are early signs of recovery in certain areas such as the gorilla clinic [5][6] - The Jun clinic and Neo Skin clinic are achieving an average spend per customer that exceeds existing clinics, indicating strong growth potential [12][13] Market Data and Key Metrics Changes - The aesthetics medicine industry in Japan is experiencing severe competition, yet customer visits have increased to 6,310,000 annually, with a high repeat rate of 72% [4][5] - The dermatological aesthetics segment is showing a higher growth rate, presenting significant growth potential [10] Company Strategy and Development Direction - The company is implementing a multi-brand strategy tailored to different market segments to meet diverse customer needs [10][14] - The focus is on enhancing the medical tourism business, particularly targeting Chinese tourists [15] - The company aims to expand its clinic network from 260 to 1,000 clinics over the next ten years [32] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that while there were negative factors impacting performance, they believe the business will improve moving forward [35][41] - The company is entering a phase of growth investment after completing business restructuring [44] Other Important Information - The company conducted its first-ever share buyback from May to July, which positively impacted share price and liquidity [22][44] - The company is considering new share issuance and partial sale by the founder to improve accessibility for a broader investor base [22][46] Q&A Session Summary Question: Are the new clinics starting up as planned? - Newly opened clinics are seeing steady customer visits, with an increase in male customers noted [24][25] Question: What is the future pricing trend? - The company is adopting a multi-brand strategy with different pricing tiers to meet varying customer needs [26] Question: Can you explain the growth strategy regarding organic and inorganic growth? - The company plans to proactively open new clinics and conduct M&A, with a strong track record of turning around acquired clinics [27][29] Question: How many clinics are you planning to open in Japan? - The company aims to increase the number of clinics to 1,000 over the next ten years [32] Question: What is the outlook for future profitability? - The company expects to secure sufficient margins and improve overall profitability as new clinics are established [34] Question: How is the company addressing the current share price trend? - The company is focusing on improving liquidity through share buybacks and considering dividend payments [43][44] Question: What are the plans for the CEO's shareholding? - The CEO is considering selling shares to improve liquidity and fund investments [46]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5] Core Views - The company reported a revenue of 859 million yuan for H1 2025, representing a year-on-year increase of 42.43%, and a net profit attributable to the parent company of 392 million yuan, up 26.65% year-on-year [1] - The company is expected to experience growth driven by new gel products and international expansion, with projected revenues of 2.194 billion yuan, 3.000 billion yuan, and 3.796 billion yuan for 2025, 2026, and 2027 respectively [4] Financial Performance Summary - In H1 2025, the gross margin was 90.68%, a decrease of 0.90 percentage points year-on-year, while the net profit margin was 45.66%, down 5.69 percentage points year-on-year [2] - The medical device segment generated 708 million yuan in revenue for H1 2025, a year-on-year increase of 33.41%, accounting for 82.45% of total revenue [3] - The functional skincare segment saw significant growth, with revenue of 121 million yuan, up 152.39% year-on-year, representing 14.10% of total revenue [3] Product and Market Development - The company has launched new high-end gel products, with expectations for increased sales in the second half of the year [4] - The company is accelerating its international expansion, having received new approvals in Thailand and obtained four international invention patents [4]

Market Overview - The medical beauty sector experienced a decline of 0.21% on August 13, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - ST Meigu closed at 3.15 with no change, trading volume of 88,100 shares, and a transaction value of 27.62 million yuan [1] - Huaxi Biological closed at 53.60, down 0.09%, with a trading volume of 40,900 shares and a transaction value of 218 million yuan [1] - Aimeike closed at 186.00, down 0.29%, with a trading volume of 32,400 shares and a transaction value of 600 million yuan [1] - Jinbo Biological closed at 301.49, down 0.49%, with a trading volume of 8,955 shares and a transaction value of 271 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 63.94 million yuan from institutional investors, while retail investors had a net inflow of 61.61 million yuan [1] - Speculative funds recorded a net inflow of 2.34 million yuan [1] Additional Stock Data - ST Meigu reported a net outflow of 3.73 million yuan, a decrease of 13.52% [2] - Huaxi Biological had a net outflow of 16.99 million yuan, a decrease of 7.78% [2] - Aimeike experienced a net outflow of 43.22 million yuan, a decrease of 7.20% [2]

Core Viewpoint - The E'min County Market Supervision Administration is actively addressing false and illegal advertisements in high-frequency consumer areas such as food, medicine, real estate, education, and healthcare, aiming to protect the public's financial and health rights through targeted regulation and collaborative enforcement [1][2][3] Group 1: Targeted Regulation - The administration focuses on key areas of concern, including food and drug safety, housing consumption traps, and medical beauty advertising, implementing strict checks and balances [1][2] - Specific actions include investigating medical advertisements for proper approvals, scrutinizing real estate ads for false promises, and regulating medical beauty ads that use absolute terms [2] Group 2: Collaborative Enforcement - A multi-departmental collaboration has been established to enhance regulatory effectiveness, involving coordination with health, housing, education, and cultural departments [2] - Online advertisements are being monitored through extensive checks, with over 60 ads reviewed and 16 illegal leads corrected [2] Group 3: Industry Self-Regulation - The administration promotes self-regulation within industries by conducting compliance training sessions and guiding companies on advertising laws to minimize legal risks [3] - Initiatives include creating educational content to help the public identify false advertisements and improve consumer awareness [3] Group 4: Future Directions - The administration plans to continue focusing on consumer concerns in daily life, ensuring that truthful and lawful advertising becomes a guiding principle for safe consumption [3]